Drug intelligence / Profile preview

ipilimumab + osimertinib

Development stage: Unknown
Lead developer: University of Utah
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of ipilimumab, a monoclonal antibody targeting CTLA-4, and osimertinib, an EGFR tyrosine kinase inhibitor. This combination is being investigated for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), with the goal of leveraging potential synergy between EGFR inhibition and immune checkpoint blockade to enhance anti-tumor activity.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on ipilimumab + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ipilimumab + osimertinib.

Explore the full profile